FIGURE 2.

Alterations of terminal fatty acid oxidation and pyruvate handling in livers of SCOT-KO mice. A, hepatic fractional ¹³C enrichments of glutamate (left) and total hepatic glutamate pools (right) 20 min after intraperitoneal injection of sodium [1,2,3,4-¹³C₄]octanoate (10 μmol/g of body weight) in P1 mice. n = 6–8/group. B, fractional ¹³C enrichments of glutamate (left) and total hepatic glutamate pools (right) 20 min after intraperitoneal injection of sodium [1,2,3,4-¹³C₄]octanoate (10 μmol/g of body weight) + unlabeled pyruvate (20 μmol/g) in livers P1 mice. n = 6–7/group. C, fractional ¹³C enrichments of glutamate 30 min after intraperitoneal injection of sodium [3-¹³C]pyruvate (10 μmol/g of body weight) in livers of P1 mice. n = 4/group. D, short chain acylcarnitine concentrations in blood of untreated P1 mice. n = 5–10/group. E, hepatic triacylglycerol (TAG) content in livers of untreated P1 mice. n = 5–6/group. *, p < 0.05; **, p < 0.01; ***, p < 0.001 by Student's t test. Error bars, S.E.